The aim of this study was to iteratively develop and validate an 
pharmacokinetics. The lead compound was then 18 F-labeled and tested in atherosclerotic apoE Ϫ/Ϫ mice receiving a high-cholesterol diet as well as wild type murine models of myocardial infarction and heart transplant rejection.
R E S U L T S
The tetrameric peptide had the highest affinity and specificity for VCAM-1 (97% inhibition with soluble VCAM-1 in vitro). In vivo PET-CT imaging using 18 F-4V showed 0.31 Ϯ 0.02 SUV in murine atheroma (ex vivo %IDGT 5.9 Ϯ 1.5). A reliable noninvasive diagnostic strategy for detecting inflamed arterial lesions at risk for complications could help target and evaluate therapies to prevent myocardial infarction (MI) and stroke. Current clinical imaging technologies largely provide structural information (1); however, the anatomical severity of stenosis does not sufficiently gauge the risk of vascular events (2) . Molecular imaging approaches now in development aim to interrogate biological processes rather than morphology (1, 3, 4) .
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Vascular cell adhesion molecule (VCAM)-1 plays a cardinal role in atherosclerotic plaque progression (5) (6) (7) . Activated endothelial cells that line the tissue-blood interface express VCAM-1, as can lesional macrophages and smooth muscle cells (5-7). VCAM-1 mediates inflammatory cell adhesion through interaction with the integrin very late antigen-4 (8). The early induction, confinement of expression to atherosclerotic lesions, and accessible position in proximity to the blood pool render VCAM-1 an attractive imaging biomarker.
We (9,10) and others (11, 12) have imaged VCAM-1 as a proof-of-principle in inflammatory disease, for instance with targeted nanoparticles for magnetic resonance imaging (MRI). Although providing early efficacy data, these agents face practical regulatory hurdles that prevent rapid clinical development. Despite the specific advantages of positron emission tomography (PET), the increasing clinical availability of PET-computed tomography (CT) scanners, and the unmet need for noninvasive identification of high-risk vascular lesions, relatively few targeted PET agents exist for plaque imaging (13, 14) . [ (15) (16) (17) and is clinically approved for cancer imaging. 18 FDG uptake presumably indicates glucose transport, and uptake associates with macrophage (18) and neovessel content (19) . Studies in patients undergoing endarterectomy (17) showed increased 18 FDG signal in macrophage-rich carotid arteries. However, there remains a need for development of agents that selectively target inflammation in plaques and that have lower background uptake in metabolically highly active myocardial tissue than 18 FDG to facilitate coronary imaging.
Here we describe the design, synthesis, evaluation, and use of a new PET imaging agent with optimized pharmacokinetics and specificity for VCAM-1. The overall design of this peptide-based agent hinged on: 1) preference of PET-CT as a hybrid clinical imaging modality with high-sensitivity (PET) combined with detailed anatomical information (CT); 2) choice of 18 F as a clinical PET tracer with a short half-life; 3) harnessing powerful signal amplification strategies (multivalency of affinity ligand and VCAM-1-mediated cell internalization); and 4) choice of a probe design that would ultimately allow for rapid clinical translation.
M E T H O D S
Agent synthesis. A number of VCAM-1 specific peptide sequences have been identified by phage display technology (9,10) containing linear and cyclic heptapeptides (Table 1) . To facilitate comparative testing of agents in the current work, we first derivatized 3 lead peptides with the chelator 1,4,7,10-tetraazadodecane-1,4,7,10-tetraacetic acid (DOTA) and labeled them with 111 Indium. Peptides were synthesized with standard N␣-9-fluorenylmethoxycarbonyl chemistry, followed by high-performance liquid chromatographic analysis, which demonstrated Ͼ98% purity. The labeling yields of 111 In-DOTA derivatives were Ͼ99% at specific activities of 30.8 GBq/mol. On the basis of initial comparative results, we then redesigned the best peptide (sequence VHPKQHR, linker GGSYKKK, tetramer) and labeled it with 18 Fluorine with a benzaldehyde method (20) . The synthesis of the lead compound, named 18 F-4V, was automated with a PETsynthRN synthesizer (Nebeling GmbH, Drolshagen, Germany) followed by high-performance liquid chromatographic purification. We also synthesized a fluorescent version of 18 In-labeled peptides were added to murine heart endothelial cells (MHEC) (21) and incubated at 37°C for 1 h. Cells were harvested from the plates, and the radioactivity was measured via gamma well counter. To evaluate specificity for VCAM-1, 18 F-4V (0.20 g) was preincubated with 5ϫ murine VCAM-1 or saline and then added to MHEC. Mouse models. Apolipoprotein E (ApoE) Ϫ/Ϫ mice had an average age of 45 weeks and were on a high-cholesterol diet (Harlan Teklad, Madison, Wisconsin), which produces reliable VCAM-1 expression in atherosclerotic plaques located in the aortic root (10) . To test imaging in the setting of therapy, we treated a cohort of apoE Ϫ/Ϫ mice with atorvastatin (enriched in diet, 0.01% wt/wt) (10). Two additional disease entities known to increase VCAM-1 expression were imaged: MI was induced by coronary ligation (22) , and heterotopic allograft heart transplantation from BALB/C into C57/B6 mice was performed (23) . Mice were anesthetized for all procedures (isoflurane 2% to 3% v/v, Baxter). The institutional subcommittee on research animal care approved all animal studies.
BIODISTRIBUTION STUDIES.
The blood half-life of candidate probes was determined with serial retroorbital bleeds after injection of 150 Ci of a given agent into the tail vein of 6 wild-type mice. After sacrifice (4 h), mice were perfused with 10 ml of saline. Organs were harvested, and their activity was recorded with a gamma counter (1480 Wizard 3-inch, PerkinElmer, Waltham, Massachusetts). Biodistribution data were corrected for decay and residual activity at the injection site. Oil Red O staining depicted the distribution of plaques in apoE Ϫ/Ϫ aortas, which were subsequently analyzed by digital autoradiography. To evaluate the in vivo specificity of 18 F-4V, cohorts of mice were preinjected with an antibody targeted to VCAM-1 (BD Pharmingen, San Diego, California), followed by 18 F-4V 60 min later. The PET data were reconstructed with ordered subsets expectation maximization and filtered back projection algorithms (24) , with a spatial resolution approaching approximately 1 mm. For quantitation of PET signal, regions of interest were placed in the aortic root on the basis of anatomical CT imaging. The CT X-ray source was used with a power of 80 kVp and 500 A, an exposure time of 370 to 400 ms, and an isotropic resolution of 90 m. During CT acquisition, Isovue-370 (Bracco Diagnostics, Princeton, New Jersey) was infused intravenously.
Quantitative reverse transcription polymerase chain reaction. To validate in vivo PET data, we correlated 18 F-4V uptake to expression of VCAM-1 and CD68 quantified by multiplex quantitative polymerase chain reaction (PCR) (TaqMan, Applied Biosystems, Foster City, California) with glyceraldehyde-3-phosphate dehydrogenase as an endogenous control. Statistics. Results are expressed as mean Ϯ SEM. Unpaired data were compared with the unpaired 2-sided t test, and paired data were compared with the paired 2-sided t test. The significance level in all tests was 0.05. Due to space limitations of the format, the Methods section has been abbreviated.
R E S U L T S
In vitro and in vivo screening of candidate peptides. To determine the affinity of candidate compound, we measured displacement of radioactively tagged TLP bound to purified VCAM-1 by cold F-labeled tetrameric peptide-PET imaging reporter targeted to VCAM-1.
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MLP, MCP, or TLP. Sigmoidal concentrationdependence curves were observed with an R 2 of 0.984 (TLP), 0.9880 (MLP), and 0.9934 (MCP) (Fig. 1A) . The tetrameric, linear peptide formulation TLP had a half-maximal inhibitory concentration for VCAM-1 of 86.6 nmol/l, 232-and 349-fold better than MCP or MLP, respectively.
We then screened candidates against MHEC, which constitutively express high levels of VCAM-1 (21), and observed a significantly higher accumulation of TLP than MLP or MCP (Fig 1B) . Finally, candidate peptides injected into apoE Ϫ/Ϫ mice facilitated evaluation of uptake into atheroma. TLP showed the highest percent injected dose/gram tissue (%IDGT) in excised aortas 60 min after injection (4.8-fold higher than MLP and 2.4-fold higher than MCP), corroborated by highest signal on autoradiography exposure (Figs. 1C and 1D) . (Fig. 2) . Cell uptake experiments involving inhibition with soluble VCAM-1 resulted in a 97% activity decrease, demonstrating a specificity of 18 F-4V (Fig. 3A) . We injected 18 F-4V into 6 wild-type mice to established the blood half-life and biodistribution. 18 
18
F-4V accumulates in atherosclerotic plaques. We assessed uptake of 18 F-4V into atherosclerotic plaques in excised aortas of wild-type mice, apoE Ϫ/Ϫ mice, and apoE Ϫ/Ϫ mice treated with atorvastatin. Uptake in the aortic root was 312% higher in apoE Ϫ/Ϫ mice (p Ͻ 0.05) (Fig. 3B ), when compared with wild type. Autoradiography and en face Oil Red O staining confirmed that activity concentrated in atherosclerotic plaques (Fig. 3C) . Nahrendorf et al.
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Treatment with atorvastatin significantly reduced uptake of 18 F-4V (Fig. 3B) . To assess the selectivity of in vivo uptake of 18 F-4V for VCAM-1, we pre-injected 250 g of monoclonal VCAM-1 antibody into apoE Ϫ/Ϫ mice. This procedure reduced the uptake of the agent to levels seen in wild-type mice (Fig. 3B) .
The cellular and microscopic distribution of the agent was assessed with a fluorescently labeled version of the tetrameric peptide and showed good correlation with immunoreactive VCAM-1 expression (Fig. 4) . The probe distributed mainly to endothelial and subendothelial layers and colocalized primarily with endothelial cells.
In vivo PET-CT imaging of 18
F-4V detects VCAM-1 expression in atherosclerotic plaques. Dynamic PET imaging identified 60 to 120 min after injection as the optimal time period for acquisition ( Fig. 5) . At that time, we found a strong focal PET signal in the aortic root of apoE Ϫ/Ϫ mice (Fig. 6 ). Hybrid imaging facilitated unambiguous allocation of the PET signal to the vascular bed of interest identified by contrast-enhanced vascular CT. Absolute quantification of PET signal (standard uptake value) showed significantly higher values in the root of apoE Ϫ/Ϫ compared with atorvastatin-treated apoE Ϫ/Ϫ or wild-type mice (Fig. 6 ).
Uptake of 18
F-4V closely correlates with inflammatory gene expression. After imaging, we determined the ex vivo activity of aortic sections and assessed gene expression by reverse transcription (RT)-PCR (Fig.  7) . 18 F-4V-derived activity correlated with VCAM-1 mRNA levels (R ϭ 0.79, p ϭ 0.03) (Fig. 7) . We also explored gene expression of CD68, a macrophage biomarker of inflammatory atherosclerosis (R 2 ϭ 0.50, p Ͻ 0.05).
VCAM-1 imaging in other cardiovascular disorders.
Given the aforementioned results, we reasoned that 18 F-4V PET imaging could apply to a variety of other cardiovascular conditions (e.g., ischemic myocardial injury or transplant rejection), situations that might involve widespread VCAM-1-mediated monocyte recruitment. We assayed VCAM-1 transcript levels in mice 5 days after MI and on day 7 after heart transplantation. The VCAM-1 mRNA levels increased 20-and 3-fold, respectively. As in atherosclerosis, inflamed myocardium had considerable uptake of 18 F-4V (Fig. 8) . The specificity of this uptake was investigated in vivo with blocking of uptake by preinjection with a VCAM-1 targeted antibody, which reduced the infarct activity/background ratio from 3.1 to 1.4 and, in the transplant model, the graft/ background ratio from 2.4 to 1.4.
D I S C U S S I O N
The central role of VCAM-1 in the evolution of inflammatory vascular lesions and its exposed accessible position on the endothelial surface render this adhesion molecule an attractive imaging target for atherosclerosis, MI, and transplant rejection. Here we show that PET-CT can image VCAM-1 and describe the design, synthesis, and validation of the novel PET imaging agent 18 F-4V. The technique detects VCAM-1 expression in murine aortas, vessels with a diameter considerably smaller than epicardial human coronary arteries. We also show that targeting VCAM-1 is useful for imaging of other cardiovascular diseases.
The initial design of 3 candidate probes derived from peptides identified by phage display (9, 10) . Although all of these peptides did target VCAM-1, the modified imaging probes differed in their affin- F-4V (Cy5-4V) was used to explore microscopic and cellular agent distribution. In fluorescence micropscopy, the endothelial and subendothelial layers of an atherosclerotic plaque in the aortic root show strong uptake, whereas autofluorescence in the FITC channel is negligible. On adjacent sections, VCAM-1 and endothelial staining (CD31) colocalize with the agent, with some uptake in macrophages (MAC-3) and smooth muscle cells (␣-actin). Magnification 400ϫ.
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ity, molecular weight, and pharmacokinetics. TLP, the lead peptide with the highest affinity and most favorable pharmacokinetics, had an arborizing, tetrameric design. The multivalency of TLP resulted in superior performance, a phenomenon previously observed for targeted nanoparticles (25) . Consequently, we derivatized TLP with the clinical PET tracer 18 F and investigated 18 F-4V in a number of in vitro and in vivo experiments. In vitro, preincubation of the agent with soluble VCAM-1 almost completely blocked cellular uptake. In vivo, pre-injection of a VCAM-1-specific antibody blocked 18 F-4V uptake, and 18 F-4V signal correlated closely with VCAM-1 mRNA levels in respective vascular territories (R ϭ 0.79). Areas of highest activity colocalized with Oil Red O-stained atherosclerotic plaques on excised aortas. Statin treatment, known to reduce VCAM-1 expression (26) , diminished the ex vivo and in vivo 18 F-4V signal. The biodistribution of 18 F-4V proved favorable, with low background uptake in undiseased vessel walls and a short blood half-life, which will allow for rapid injection-imaging sequences.
VCAM-1 expression contributes to the pathophysiology of a variety of other cardiovascular conditionsfor instance to inflammation after ischemic injury (11, 22, 27) . Myocardial infarction triggers a profound influx of neutrophils and monocytes on days 1 to 6 after ischemia, and the quantity as well as quality of the myeloid cell influx determine the degree of ensuing heart failure and therefore prognosis (27) (28) (29) . As an integral part of the recruiting mechanism for monocytes, VCAM-1 expression could gauge the degree of inflammation after MI. We found a substantial increase of VCAM-1 mRNA levels in mice on day 5 after coronary ligation, consistent with 18 F-4V accumulation. VCAM-1 also rises during cardiac transplant rejection and promotes monocyte recruitment into the graft (30, 31) . Mononuclear phagocytes constitute up to 60% of the inflammatory cell population during parenchymal rejection (32) . Patients after heart trans- Dynamic positron emission tomography (PET) imaging identified 60 to 120 min after injection as a suitable time window, with low blood signal and high activity in the target. The blood activity was measured in the left ventricular blood pool. Imaging signal in the blood pool and the aortic region is plotted (A) and shown over time in short-(B) and long-axis (C) PET-computed tomography (CT) acquisitions. Initially, acquisition times were shorter due to high count rates, whereas progressing decay of 18 F necessitated longer acquisition times in later acquisitions.
Nahrendorf et al. VCAM-1 PET-CT plantation would greatly benefit from noninvasive assessment of rejection, because repetitive endomyocardial biopsies, the current reference standard, involve invasion and carry a risk of complication. VCAM-1 mRNA levels increased in heterotopically transplanted cardiac allografts, and the 18 F-4V signal indeed rose in these rejecting allografts.
Compared with previous efforts to visualize VCAM-1 by MRI or ultrasound (9,10,12,33), 18 F-4V imaging provides a number of potential advantages. Positron emission tomography affords absolute signal quantification and will allow robust and noninvasive measurement of VCAM-1 expression, critical for assessment of individual patients as well as patient cohorts in clinical trials. Not only do high affinity and specificity for a target essential to lesion biology support the translatability of 18 F-4V, so too does its employment of a clinically established PET tracer and its clinically useful probe design. The inherent sensitivity of PET allows detection of targets at concentrations that are several orders of magnitude lower than are seen with other modalities, for instance MRI. This feature might have particular importance when targets are as small as atherosclerotic plaques. 
